Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Jul 01, 2021 6:56am
284 Views
Post# 33478530

RE:RE:RE:Nothing

RE:RE:RE:Nothing

Dead on Oden.

Yes it seems all we will be told now is via the Quarterly and then not much.Watched ‘live’ as a guest and struggled to keep up with what little there was while simultaneously attempting to contextualise. Haven`t been able to refer back so the following is from suspect memory.

 

NMIBC - just rattled through the figures in the table. Can only hope the high ‘no response’ is attributable to under-dosing of the first patients (and as Enrique says possibly P4 from Phase IB) but really looking to the patients with 2 optimal doses as per the protocol and there`s no clear picture yet.

 

Rutherrin - is it correct to recall that over 75% of rat brain tumour was destroyed with radiation alone and some lesser % by PDT in the lungs? Again little context and no clarification on whether such numbers may be transformed by adjustments to dosing the use of adjuvants or combined radiation/PDT treatment. Again rattled through and the couple of pre-submitted questions that represented the only successfully attempted dialogue were cancelled with pre-scripted stonewall answers. Come back Dr.Lilge all is forgiven!

 

These are intelligent people but the communication of information was woeful. We`ll each draw our own conclusions but no one can accuse SS of ramping the stock.

 
<< Previous
Bullboard Posts
Next >>